{"id":"NCT00600756","sponsor":"AstraZeneca","briefTitle":"Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","officialTitle":"A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2008-01-25","resultsPosted":"2012-09-12","lastUpdate":"2012-10-05"},"enrollment":798,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenic Disorders"],"interventions":[{"type":"DRUG","name":"Quetiapine XR","otherNames":["Seroquel XR"]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"Quetiapine XR","type":"EXPERIMENTAL"},{"label":"Risperidone","type":"ACTIVE_COMPARATOR"}],"summary":"The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one year. Secondary outcome measures have been selected for helping in the differentiation of the compared atypical antipsychotics. The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K","primaryOutcome":{"measure":"Responder Rate at Month 6 in the Per Protocol Population Using the Subjective Well-being Under Neuroleptics Scale, Short Version (SWN-K) Total Score","timeFrame":"6 months","effectByArm":[{"arm":"Quetiapine XR","deltaMin":136,"sd":null},{"arm":"Risperidone","deltaMin":158,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":116,"countries":["Belgium","Brazil","Bulgaria","Costa Rica","Finland","Germany","Italy","Mexico","Portugal","Romania","Russia","Spain","Switzerland","Turkey (Türkiye)"]},"refs":{"pmids":["23953270"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":391},"commonTop":["Somnolence","Insomnia","Anxiety","Constipation","Headache"]}}